Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Giulia Gasparini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2273-9773; OpenAlex author ID A5006344074. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 5 papers · 2024: 3 papers · 2025: 3 papers · 2026: 3 papers

Papers 19

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  3. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  4. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  5. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  6. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  7. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  8. Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Co-author DOI 10.1016/j.ejso.2023.02.005↗
  9. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  10. Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system. First author DOI 10.1007/s00428-023-03574-x↗
  11. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  12. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. Co-author DOI 10.1016/j.ejso.2023.03.229↗
  13. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  14. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  15. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Co-author DOI 10.1016/j.ejso.2021.01.001↗
  16. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. Co-author DOI 10.1016/j.hpb.2021.04.004↗
  17. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Co-author DOI 10.1245/s10434-021-10401-7↗
  18. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… Co-author DOI 10.1016/j.ejso.2020.02.013↗
  19. Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. Co-author DOI 10.3390/cancers11070893↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefano Crippa · 19 shared papers, 2019–2026 · strength 3.28
  2. Massimo Falconi · 18 shared papers, 2019–2026 · strength 3.03
  3. Giulio Belfiori · 16 shared papers, 2019–2026 · strength 2.71
  4. Stefano Partelli · 13 shared papers, 2020–2026 · strength 2.28
  5. Domenico Tamburrino · 11 shared papers, 2021–2026 · strength 2.04
  6. Marco Schiavo Lena · 10 shared papers, 2019–2026 · strength 1.83
  7. Nicolò Pecorelli · 8 shared papers, 2023–2026 · strength 1.62
  8. Diego Palumbo · 7 shared papers, 2024–2026 · strength 1.43
  9. Michele Reni · 7 shared papers, 2023–2026 · strength 1.42
  10. Francesco DE COBELLI · 6 shared papers, 2024–2026 · strength 1.25
  11. Federico De Stefano · 6 shared papers, 2023–2026 · strength 1.22
  12. Claudio Doglioni · 6 shared papers, 2019–2025 · strength 0.89
  13. Paolo Riccardo Camisa · 4 shared papers, 2024–2026 · strength 0.85
  14. Giuseppe Malleo · 4 shared papers, 2023–2026 · strength 0.75
  15. Gabriella Lionetto Lionetto · 4 shared papers, 2023–2026 · strength 0.75
  16. Claudio Luchini · 4 shared papers, 2023–2026 · strength 0.75
  17. Roberto Salvia · 4 shared papers, 2023–2026 · strength 0.75
  18. Fabio Casciani · 2 shared papers, 2026 · strength 0.46
  19. Giovanni Guarneri · 3 shared papers, 2020–2024 · strength 0.43
  20. Maria Giulia Cangi · 2 shared papers, 2023–2025 · strength 0.38
  21. Marina Macchini · 2 shared papers, 2023–2024 · strength 0.35
  22. Giulia Orsi · 2 shared papers, 2023–2024 · strength 0.35
  23. Carlos Fernández-del Castillo · 2 shared papers, 2023–2026 · strength 0.34
  24. Gianpaolo Balzano · 2 shared papers, 2020–2026 · strength 0.30
  25. Paola Mattiolo · 2 shared papers, 2023 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.